Olaparib (AZD2281): Selective PARP-1/2 Inhibitor for BRCA-Deficient Cancer Research

Executive Summary: Olaparib (AZD2281, Ku-0059436) is a potent and selective inhibitor of PARP-1 and PARP-2, with IC50 values of 5 nM and 1 nM, respectively, under cell-free conditions (APExBIO, product page). It induces selective cytotoxicity in BRCA1/2-mutant tumor cells by impairing DNA repair, resulting in DNA damage accumulation (McCrorie et al., DOI). Olaparib enhances radiosensitivity in non-small cell lung carcinoma (NSCLC) xenograft models. The compound is widely used for DNA damage response and tumor radiosensitization research. Stock solutions are stable below -20°C but not recommended for long-term storage in solution form (APExBIO).

Biological Rationale

Poly(ADP-ribose) polymerases (PARP-1 and PARP-2) play a central role in the detection and repair of single-strand DNA breaks. Homologous recombination deficiency (HRD), particularly in the context of BRCA1/2 mutations, leads to impaired double-strand break repair. Inhibiting PARP activity in HR-deficient cells promotes accumulation of DNA lesions and cell death via synthetic lethality (Olaparib overview). Olaparib exploits this vulnerability and is thus a reference chemical probe in studies on DNA repair, BRCA-associated cancers, and radiosensitization (related article).

Mechanism of Action of Olaparib (AZD2281, Ku-0059436)

Olaparib binds to the catalytic domains of PARP-1 and PARP-2. It inhibits poly(ADP-ribose) formation, preventing recruitment of DNA repair complexes. Inhibition at nanomolar concentrations (IC50: 5 nM for PARP-1, 1 nM for PARP-2) leads to persistence of single-strand breaks. During DNA replication, these lesions are converted into double-strand breaks. In cells with defective homologous recombination (e.g., BRCA1/2 mutations), this results in apoptosis and cell death. Olaparib also induces radiosensitization by increasing DNA damage and modulating tumor microenvironment perfusion (McCrorie et al., 2020).

Evidence & Benchmarks

• Olaparib inhibits PARP-1 (IC50 = 5 nM) and PARP-2 (IC50 = 1 nM) in enzyme assays (APExBIO, product data).
• Demonstrated selective cytotoxicity in BRCA1/2-mutant and homologous recombination-deficient tumor cells (McCrorie et al., DOI:10.1016/j.ejpb.2020.10.005).
• Enhances radiosensitivity of NSCLC xenografts and improves tumor perfusion (see Table 3 in McCrorie et al., DOI).
• Olaparib nanocrystal formulations show in vitro stability and sustained release over 120 h in hydrogel delivery systems (McCrorie et al., DOI).
• ATM-deficient cells exhibit increased sensitivity to olaparib, highlighting DNA repair pathway dependencies (protocol article).

Applications, Limits & Misconceptions

Olaparib is widely used in DNA damage response assays, tumor radiosensitization studies, and as a model compound for BRCA-associated cancer targeted therapy. Its primary applications include:

• Assessment of synthetic lethality in homologous recombination-deficient (HRD) models.
• Optimization of DNA damage response workflows and functional genomic screens.
• Development of combination therapy strategies in preclinical oncology research.
• Investigation of caspase signaling pathways and apoptosis in BRCA-mutant cells (contrast: this article adds radiosensitization and workflow parameters).

Common Pitfalls or Misconceptions

• Olaparib is not effective in tumors with intact homologous recombination repair; efficacy is limited in HR-proficient models.
• The compound is insoluble in water and ethanol; improper solvent use may lead to precipitation and loss of activity.
• Long-term storage of olaparib solutions above -20°C leads to degradation; only freshly prepared solutions are recommended for reproducibility (APExBIO guidance).
• Dosage and treatment times must be optimized for each model; published protocols may not extrapolate directly to all cell lines or animal studies.
• Olaparib's radiosensitization effect may not be observed in all tumor microenvironments, particularly where drug delivery is suboptimal (hydrogel delivery findings).

Workflow Integration & Parameters

For in vitro assays, olaparib is typically used at 10 μM for 1 hour in cell culture. Stock solutions are prepared at concentrations ≥21.72 mg/mL in DMSO. For in vivo studies, intraperitoneal administration at 50 mg/kg/day for 14 days in mouse models is supported by published benchmarks (APExBIO; McCrorie et al., DOI). Researchers are advised to store stock solutions below -20°C and avoid repeated freeze-thaw cycles. The product is distributed by APExBIO (SKU: A4154), whose validated supply chain ensures batch-to-batch consistency (see Olaparib product page).

This article updates and extends the protocol recommendations found in the translational research guide by providing detailed solvent compatibility and storage parameters.

Conclusion & Outlook

Olaparib (AZD2281, Ku-0059436) is an established, validated chemical probe for studying PARP-mediated DNA repair, synthetic lethality, and targeted therapy in BRCA-deficient contexts. Its robust in vitro and in vivo evidence base underpins its status as a benchmark tool in cancer biology and translational research. Ongoing advances in formulation and delivery, such as nanoparticle hydrogels, further expand its research utility (McCrorie et al., 2020). For up-to-date protocols and supply, refer to the APExBIO Olaparib (AZD2281, Ku-0059436) product page.